Shots:
- Hansoh has reported P-III (ARTEMIS-011) trial data assessing risvutatug rezetecan (HS-20093), a B7-H3–directed ADC, vs CT in pts with osteosarcoma who had progressed or relapsed after receiving ≥2 prior lines of systemic therapy
- Trial met its 1EP of improved PFS as assessed by the IRC, with consistent benefits observed across 2EPs, incl. OS & investigator-assessed PFS; data to be presented at an upcoming medical congress
- Additionally, Hansoh Pharma plans to initiate discussions with China’s CDE in the near term to advance preparations for a BLA
Ref: Hansoh | Image: Hansoh | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
